BERLIN (dpa-AFX) - Biocartis, a molecular diagnostics company, Monday
announced expansion of its partnership with Merck KGaA (MKGAY.PK) in the Middle
East and North Africa (MEA) region to improve availability of RAS biomarker
testing for colorectal cancer patients.

RAS biomarker testing, which is not readily available in all parts of the world,
is used to determine whether colorectal cancer is positive for KRAS or NRAS gene
mutation thereby helping oncologists to take timely treatment decisions.

Biocartis' Idylla KRAS Mutation Test and Idylla NRAS-BRAF Mutation Test rapidly
determine the RAS biomarker status in mCRC tumor tissue samples. Biocartis
Idylla Platform is easy to use, and can be deployed in any user setting.

More than 1.9 million new cases of colorectal cancer, the third most common
cancer, are reported annually.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX